Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209992 | 0.94 | CCR2 (0.70) | CCR2CCR5 | |
| SCHEMBL5208241 | 0.93 | CCR2 (0.67) | CCR2CCR5 | |
| SCHEMBL5211261 | 0.93 | CCR2 (0.69) | CCR2CCR5 | |
| SCHEMBL5241768 | 0.93 | CCR2 (0.67) | CCR2CCR5 | |
| SCHEMBL5208849 | 0.93 | CCR2 (0.69) | CCR2CCR5 | |
| SCHEMBL7684955 | 0.93 | CCR2 (0.66) | CCR2CCR5 | |
| SCHEMBL5238081 | 0.93 | CCR5 (0.72) | CCR2CCR5 | |
| SCHEMBL7682451 | 0.93 | CCR2 (0.66) | CCR2CCR5 | |
| SCHEMBL5209195 | 0.93 | CCR2 (0.66) | CCR2CCR5 | |
| SCHEMBL5205096 | 0.92 | CCR2 (0.72) | CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040103-B1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2007-03-14 | — | — | EP | claimed |
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | claimed |
| US-20050154016-A1 | Preventives for hiv infection | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | US | claimed |
| EP-1498138-A1 | PREVENTIVES FOR HIV INFECTION | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | claimed |
| EP-1498125-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | claimed |
| US-6172061-B1 | AIDS THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | claimed |
| US-6166006-A | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-26 | — | — | US | claimed |
| JP-11263764-A | — | — | None | — | — | JP | disclosed |
| US-12016935-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016935-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| US-20200405889-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | WASHINGTON UNIVERSITY (US) | 2020-12-31 | — | — | US | disclosed |
| US-20170348442-A1 | COMPOSITIONS AND METHODS FOR DETECTING CCR2 RECEPTORS | WASHINGTON UNIVERSITY (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348442-A1 | COMPOSITIONS AND METHODS FOR DETECTING CCR2 RECEPTORS | WASHINGTON UNIVERSITY (US) | 2017-12-07 | — | — | US | disclosed |
| US-6268354-B1 | Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-31 | — | — | US | disclosed |
| US-6172061-B1 | AIDS THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| US-6166006-A | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1039899-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| JP-2000128782-A | ANILIDE DERIVATIVE-CONTAINING CCR5 ANTAGONIST | TAKEDA CHEM IND LTD | 2000-05-09 | — | — | JP | disclosed |
| JP-H11263764-A | ANILIDE DERIVATIVE AND ITS PRODUCTION AND USE | TAKEDA CHEM IND LTD | 1999-09-28 | — | — | JP | disclosed |
| WO-1999032100-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154016-A1 | Preventives for hiv infection | CCR5, CCR2, CCR1 | CCR2 2/4885CCR5 1/4885 |
| US-20170348442-A1 | COMPOSITIONS AND METHODS FOR DETECTING CCR2 RECEPTORS | CCR2, CCR1, CCR3 | CCR2 1/4885CCR5 4/4885 |
| US-20200405889-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | CCR2, CCR1, CCR5 | CCR2 1/4885CCR5 3/4885 |
| US-12016935-B2 | Methods for detecting CCR2 receptors | CCR2, CCR1, CCR5 | CCR2 1/4885CCR5 3/4885 |
| US-20050245537-A1 | Use of compounds having ccr antagonism | CCR1, CCR3, CCR2 | CCR2 3/4885CCR5 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.